Baseline demographic and behavioural characteristics of South African women at high risk of HIV acquisition stratified by HIV status [25].

#<p>Acute HIV Infection.</p

Unadjusted and adjusted analysis of signs and symptoms associated with acute HIV Infection.

*<p>Model for behavioural and demographic factors adjusted for age in years, relationship status, education and age at sexual debut (data not shown), while model for symptoms and signs adjusted for sore throat, rash, loss of appetite, weight loss, genital ulcers and vaginal discharge.</p>**<p>Risk score model adjusting for age, sore throat, rash, loss of appetite, weight loss, genital ulcers and vaginal discharge.</p

Signs and symptoms associated with acute HIV infection.

*<p>Odds Ratio adjusted for repeated measures.</p><p>Note: Signs and symptoms reported with <5% frequency in the AHI cases or p>0.15 were omitted. These included splenomegaly, anal ulcers, swollen joints, gingivitis, observed fever, aseptic meningitis, peripheral neuropathy, conjunctivitis, hepatomegaly, photophobia, parasthaesia, retro-orbital headache and neck stiffness.</p

Sensitivity and Specificity for different number of signs and symptoms.

*<p>POCT: point of care test.</p

Signs and symptoms according to HIV diagnostic test.

*<p>Fisher’s Exact test.</p

Haematologic parameters and median viral load prior to infection and by post-infection month.

<p>Normal values are as follows: Hb 12.0–16.5 g/dl, MCV 76–99 fl, MCH 26–34 pg, RDW 11–16%. (*Note: The post-seroconversion visit refers to the first visit after identification of acute infection and was at a median of 41.5 days post-infection (range 15–104). Also, since acute infections were identified at different time points, not all participants have data at each month post-infection.)</p

Iron studies.

<p>Normal ranges: Fe 9.0–30.4 µmol/L, B12 132–857 pmol/L, Folate >12.19 nmol/L, ferritin 20–300 ng/mL.</p

Accumulating resistance of CAP257 clones to broadly neutralizing monoclonal antibodies targeting V2 and the CD4bs.

<p>The sensitivity of nine CAP257 clones from 7, 30, 54, 93, and 174 weeks p.i. to broadly neutralizing antibodies targeting the four known sites of vulnerability was measured in a TZM-bl assay. The timing of wave 1 (red), wave 2 (green), and wave 3 (brown) neutralization is summarized above with arrows. Increases in IC₅₀ relative to the 7 week clone are colored as follows: 5–10 fold (yellow), >10 fold (orange), complete neutralization resistance (red).</p

CAP257 broadly neutralizing antibodies develop sequentially in three distinct waves.

<p><b>A</b>) Longitudinal neutralization of the autologous CAP257 virus (black) and 37 heterologous viruses neutralized by CAP257 plasma at titers >1∶100. The ID₅₀ titers (y-axis) are shown versus weeks p.i. (x-axis). Three peaks in heterologous neutralization titers at 67, 122, and 213 weeks p.i. are indicated with dotted lines. Heterologous viruses are colored according to subtype (A = green, B = blue, C = red). <b>B</b>) A summary of the three waves of heterologous neutralization defined by a representative virus, superimposed over the neutralization kinetics shown in <a href="http://www.plospathogens.org/article/info:doi/10.1371/journal.ppat.1003738#ppat-1003738-g001" target="_blank">Figure 1A</a>. Wave 1 was subtype C specific and is colored red. Wave 2 neutralized viruses from all three clades and is colored green. Wave 3 is colored brown. <b>C</b>) Adsorption of heterologous neutralization at the peak of each of the three waves. Percentage inhibition (y-axis) is shown versus plasma dilution (x-axis). Untreated plasma is shown in black, blank beads in grey and beads coated with recombinant proteins are shown in red (wave 1), blue/green (wave 2) or brown (wave 3).</p

Prevalence of anaemia (Hb<12g/dL) prior to (time = 0) and in the months following acute HIV infection vs. median HIV viral load (copies/mL).

<p>*Note: month 1 represents the first post-infection visit which occurred at a median of 42 days post-infection (range 16-86).</p